Multi-target cell and gene therapiesfor unmet medical needs
Aurealis 4-in-1 multi-target cell and gene therapy platform is the game-changing solution for complex multi-factorial diseases.
Discover how our technology is re-defining the treatment of chronic wounds (diabetic foot ulcers, venous leg ulcers), cancers (ovarian, peritoneal, bladder), and beyond.
THE TEAM, THE SCIENCE & the outcome
THE AUREALIS TEAM
At Aurealis Therapeutics, we are passionate about advancing science to make a difference for patients suffering from chronic wounds, deadly cancers, inflammatory diseases.
Meet the Management Team, the Scientific Advisors, the Board of Directors, and the Aurealis Therapeutics Team Members who make it happen.
THE SCIENCE
Our team takes pride in mastering the most advanced cell and gene therapy science, and making work in real life, from the lab to the clinic.
Discover how our multi-target cell and gene therapy platform allows to modulate tissue microenvironment and tackle complex multi-factorial diseases.
THE OUTCOME
Generating pre-clinical, clinical and health-economic evidence is how we want to make a difference. Seeing non-healing wounds heal again, seeing how cancer deaths can be prevented, and ultimately improving patient outcome – this is what matters the most to us.
Aurealis Therapeutics Completes Patient Recruitment in DIAMEND Phase 2 Diabetic Foot Ulcer Clinical Trial of AUP-16
Aurealis Therapeutics, a clinical-stage Swiss-Finnish company developing multi-target cell and gene therapies for chronic wounds and cancer, announced today the successful completion of patient recruitment in its DIAMEND AUP-16 Phase-2...
Interview with Laurent Décory COO at Aurealis Therapeutics | Career journey, AUP-16 advancements and global partnerships
At Aurealis Therapeutics, our mission is to revolutionize the treatment of chronic wounds, cancer, and inflammatory diseases with our multi-target cell and gene therapy platform. Central to this mission is...
Aurealis Therapeutics Enhances Board of Directors Expertise by Appointing Tuomo Pätsi as New Member
Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, is pleased to announce the appointment of Tuomo Pätsi as a new member of...
Aurealis Therapeutics Concludes Successful Partnering Week in China
Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, announced the successful completion of its partnering visit to China from 13-17 May, 2024....
Interview with Hanna-Riikka Kärkkäinen Head of Quality and Regulatory Affairs at Aurealis Therapeutics | Professional career, AUP-16 PRIME designation, FDA Advice & more
What was the journey that took Hanna-Riikka Kärkkäinen to her current role as Head of Quality and Regulatory Affairs? What does having the PRIME designation for AUP-16 mean? What was...
Half of the Patients Successfully Recruited and Randomized in Aurealis Therapeutics DIAMEND AUP-16 Phase-2 Study
Zug, Switzerland and Kuopio, Finland, March 11, 2024. Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, announced today the successful recruitment and...
